+612 9045 4394
Drug Resistance in Leukemia and Lymphoma III : Advances in Experimental Medicine & Biology (Springer) - R. Pieters

Drug Resistance in Leukemia and Lymphoma III

Advances in Experimental Medicine & Biology (Springer)

By: R. Pieters (Editor), Gertjian J. L. Kaspers (Editor), A. J. P. Veerman (Editor)

Hardcover Published: 30th September 1999
ISBN: 9780306460555
Number Of Pages: 638

Share This Book:


or 4 easy payments of $104.55 with Learn more
Ships in 5 to 9 business days

Cellular drug resistance is a major limitation to the success of chemotherapy of leu- kemia and lymphoma. The importance of this has now been recognized by both clinicians and scientists. It is of utmost importance to bridge the gap between laboratory and clinic in this field of research. This is the main purpose of the series of International Symposia on Drug Resistance in Leukemia and Lymphoma. These are held every three years in Am- sterdam, The Netherlands, since 1992. This book contains the proceedings of the third of these meetings, organised in 1998. The book covers all important aspects of drug resistance in leukemia and lymphoma, both in the form of extensive reviews as in manuscripts describing original data. General mechanisms of resistance are discussed, including the drug resistance related proteins p- glycoprotein, MRP (multi-drug resistance protein) and LRP (lung resistance protein), and the role of glutathione and glutathione-S-transferases. Moreover, more drug type-specific mechanisms of resistance are a topic, such as for glucocorticoids and antifolates. Much in- formation is provided on apoptosis and its regulators, and on the results of cell culture drug resistance assays. Several papers focus on the modulation or circumvention of drug resistance.

Drug Resistance Related Proteins and Glutathione
MDR1/P-gp Expression as a Prognostic Factor in Acute Leukemiasp. 1
Clinical Significance of P-Glycoprotein (P-gp) Expression in Childhood Acute Lymphoblastic Leukemia: Results of a 6-Year Prospective Studyp. 11
Prognostic Value of P-gp Expression and Related Function in Childhood Acute Leukemiap. 21
Comparison of P-Glycoprotein Expression and Function with in Vitro Sensitivity to Anthracyclines in AMLp. 29
Quinine Improves Results of Intensive Chemotherapy (IC) in Myelodysplastic Syndromes (MDS) Expressing P-Glycoprotein (PGP): Updated Results of a Randomized Studyp. 35
Treatment of Poor Prognosis AML Patients Using PSC833 (Valspodar) plus Mitoxantrone, Etoposide, and Cytarabine (PSC-MEC)p. 47
Assessment of P-Glycoprotein Expression by Immunocytochemistry and Flow Cytometry Using Two Different Monoclonal Antibodies Coupled with Functional Efflux Analysis in 34 Patients with Acute Myeloid Leukemiap. 57
Preliminary Immunocytochemical Studies of MDR-1 and MDR-3 Pgp Expression in B-Cell Leukaemiasp. 65
A Mutation in the Promoter of the Multidrug Resistance Gene (MDR1) in Human Hematological Malignancies May Contribute to the Pathogenesis of Resistant Diseasep. 71
Reproducible Flow Cytometric Methodology for Measuring Multidrug Resistance in Leukaemic Blastsp. 77
Natural Fluorescence Imaging of Leukemic Cells for Studying Uptake and Retention of Anthracyclinesp. 89
Artificial Neural Networks as Versatile Tools for Prediction of MDR-Modulatory Activityp. 95
Discordance of P-Glycoprotein Expression and Function in Acute Leukemiap. 107
Multidrug Resistance Related Proteins in Primary Cutaneous Lymphomas Christian W. van Haselen, Marcel J. Flens, Rik J. Scheperp. 119
The Lung Resistance Protein (LRP) Predicts Poor Outcome in Acute Myeloid Leukemiap. 133
MRP Expression in Acute Myeloid Leukemia: An Updatep. 141
Evidence for Functional Discrimination between Leukemic Cells Overexpressing Multidrug-Resistance Associated Protein and P-Glycoproteinp. 151
Both Pgp and MRP1 Activities Using Calcein-AM Contribute to Drug Resistance in AMLp. 161
Absolute Levels of MDR-1, MRP, and BCL-2 mRNA and Tumor Remission in Acute Leukemiap. 177
Multidrug Resistance Protein MRP1, Glutathione, and Related Enzymes: Their Importance in Acute Myeloid Leukemiap. 187
Glutathione and the Regulation of Cell Deathp. 199
Evidence for the Involvement of the Glutathione Pathway in Drug Resistance in AMLp. 205
Glutathione in Childhood Acute Leukaemiasp. 211
Apoptosis and Cell Death Regulations
Apoptosis: Molecules and Mechanismsp. 217
Activation of Apoptosis Pathways by Anticancer Drugsp. 237
BCL-2 Stimulates Apoptin-Induced Apoptosisp. 245
CD95 (Fas/Apo-1) Antigen Is a New Prognostic Marker of Blast Cells of Acute Lymphoblastic Leukaemia Patientsp. 251
Inhibition of Fas/Fas-Ligand Does Not Block Chemotherapy-Induced Apoptosis in Drug Sensitive and Resistant Cellsp. 259
Effects of PARP Inhibition on Drug and FAS-Induced Apoptosis in Leukaemic Cellsp. 267
Apoptotic Fraction in Childhood ALL Assessed by DNA in Situ Labelling Is Ploidy Independentp. 281
PCNA Bearing Structures Are Retained in Apoptotic Phase of Childhood ALL Cell Cyclep. 289
Apoptosis Corrected Proliferation Fraction in Childhood ALL Is Related to Karyotypep. 297
Proliferation and Apoptosis Does Not Affect Presenting White Cell Count in Childhood ALLp. 305
Apoptosis by Anthracyclines at Therapeutic Concentrations in MDR1+ Human Leukemic Cellsp. 313
BCL-2 Expression in Childhood Leukemia versus Spontaneous Apoptosis, Drug Induced Apoptosis and in Vitro Drug Resistancep. 325
Comparison of BCL-2 and Bax Protein Expression with in Vitro Sensitivity to Ara-C and 6TG in AMLp. 335
Synthetic Cyclin Dependent Kinase Inhibitors: New Generation of Potent Anti-Cancer Drugsp. 341
Factors Contributing to the Resistance to Apoptosis Induced by Topoisomerase I Inhibitors in Vincristine Resistant Cellsp. 355
Two Distinct Modes of Oncoprotein Expression during Apoptosis Resistance in Vincristine and Daunorubicin Multidrug-Resistant HL60 Cellsp. 365
Risk Factors and Cell Culture Assays
Genetic Abnormalities and Drug Resistance in Acute Lymphoblastic Leukemiap. 383
Resistance Testing and Mechanisms of Resistance in Childhood Leukemia: Studies from Amsterdamp. 391
Pharmacokinetics of Anticancer Drugs in Vitrop. 397
Down Syndrome and Acute Myeloid Leukemia: Lessons Learned from Experience with High-Dose Ara-C Containing Regimensp. 409
Cellular Drug Resistance in Childhood Acute Myeloid Leukemia: A Mini-Review with Emphasis on Cell Culture Assaysp. 415
Is in Vitro Sensitivity of Blast Cells Correlated to Therapeutic Effect in Childhood Acute Lymphoblastic Leukemia?p. 423
In Vitro Cytotoxic Drug Activity and in Vivo Pharmacokinetics in Childhood Acute Myeloid Leukemiap. 429
Prognosis in Adult AML Is Precisely Predicted by the Disc-Assay Using the Chemosensitivity-Index C[subscript 1]p. 437
Drug Resistance Testing of Acute Myeloid Leukemia in Adults Using the MTT Assayp. 445
MTT Assay for Drug Resistance in Childhood Acute Leukemia and Effect of Cyclosporin and Interferon: A Preliminary Reportp. 453
Differential Antileukemic Activity of Prednisolone and Dexamethasone in Freshly Isolated Leukemic Cellsp. 459
Activity of Vinorelbine on B-Chronic Lymphocytic Leukemia Cells in Vitrop. 473
Studies of Some Mechanisms of Drug Resistance in Chronic Myeloid Leukemia (CML)p. 477
Clinical Sensitivity to Anthracyclines in Ph/BCR+ Acute Lymphoblastic Leukemiap. 489
Differential Kinetics of Drug Resistance in Human Leukaemic Cells Measured by SCGE/CLSMp. 501
Demonstration of Differences in Drug Resistance by Direct Testing of DNA Excision Repair Activity following Standard and Liposomal Daunorubicin Exposure in Normal Paediatric Marrow Using High Resolution CLSMp. 509
Microsatellite Instability Assessment in Prediction of Drug Resistance in Childhood Burkitt's and Large Cell Diffuse Malignant Non-Hodgkin Lymphoma (MNHL)p. 517
High Resolution Confocal Laser Scanning Microscopy Analysis of DNA Excision Repair Capability in Small Volume Marrow Samples Exposed to DNA Directed Treatment Moietiesp. 527
Defining the Optimal Dosage of Methotrexate for Childhood Acute Lymphoblastic Leukemia: New Insights from the Lab and Clinicp. 537
Mechanisms of Methotrexate Resistance in Acute Leukemia: Decreased Transport and Polyglutamylationp. 543
Lack of Cross-Resistance between Prednisolone and Methotrexate in Childhood Acute Lymphoblastic Leukemia? A Preliminary Analysisp. 551
Nucleoside Analogues and Growth Factors
New Developments in the Treatment of Acute Myeloid Leukemiap. 557
Aphidicolin Markedly Increases the in Vitro Sensitivity to Ara-C of Blast Cells from Patients with AMLp. 567
Common Resistance Mechanisms to Nucleoside Analogues in Variants of the Human Erythroleukemic Line K562p. 571
Expression of DNA Mismatch Repair Proteins in Acute Lymphoblastic Leukaemia and Normal Bone Marrowp. 579
Effects of CSFS and Their Combinations with Chemotherapeutic Agents (Ch) on Leukemic Blasts (LB) in Children (MTT-Assay)p. 585
Glucocorticosteroid Therapy in Childhood Acute Lymphoblastic Leukemiap. 593
Glucocorticoid Induced Apoptosis in Leukemiap. 607
Glucocorticoid Resistance and the AP-1 Transcription Factor in Leukemiap. 615
The Three Asparaginases: Comparative Pharmacology and Optimal Use in Childhood Leukemiap. 621
Indexp. 631
Table of Contents provided by Syndetics. All Rights Reserved.

ISBN: 9780306460555
ISBN-10: 0306460556
Series: Advances in Experimental Medicine & Biology (Springer)
Audience: General
Format: Hardcover
Language: English
Number Of Pages: 638
Published: 30th September 1999
Country of Publication: US
Dimensions (cm): 23.39 x 15.6  x 3.51
Weight (kg): 1.09
Edition Number: 3